Study of DBC-664 Safety and Activity in Adults with Advanced or Metastatic Solid Tumors Including Endometrial and Ovarian Cancer

What this Trial Is About

Researchers are studying DBC-664 in a first-in-human Phase 1a1b open-label, multicenter trial to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor effects in adults with endometrial cancer, ovarian cancer, and other advanced solid tumors. The study aims to determine the recommended dose for expansion and confirm safety and activity in these cancers through two parts. Participants in the study will receive intravenous infusions of DBC-664. The study consists of two parts Part 1 involves dose escalation to find the recommended dose for expansion, and Part 2 involves dose expansion at that recommended dose to further evaluate safety and anti-tumor activity. Throughout the trial, participants will be monitored for safety and tolerability for up to two years and have pharmacokinetics characterized during this time. Researchers will assess tumor response and other clinical outcomes. Participation will involve regular visits for treatment and evaluations, including imaging to measure disease, and overall follow-up until study completion in 2030.

DBC-664 in Adult Patients With Solid Tumors